Official ESCRS | European Society of Cataract & Refractive Surgeons
Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Randomized trial comparing amniotic membrane transplantation with medical therapy for the treatment of ocular chemical burn

Search Title by author or title

Session Details

Session Title: Cornea: Surgical II

Session Date/Time: Sunday 08/10/2017 | 14:30-16:00

Paper Time: 15:48

Venue: Room 3.6

First Author: : H.Hasani IRAN

Co Author(s): :    A. Baradaran                    

Abstract Details


To compare the effect of amniotic membrane transplantation with medical therapy in the management of acute moderate severe ocular chemical burn.


Shahid Beheshti University of Medical Sciences


Sixty eyes of 60 patients (56 male and 4 female) with acute moderate or severe chemical (acid or alkali) burns who had a minimum follow-up of 12 months after medical or surgical treatment were enrolled in study. Eligible patients randomly received conventional medical (30 eyes) versus combined medical and surgical (30 eyes) therapies. Amniotic membrane patch sutured to entire ocular surface, within 7 days of injury in surgical group.


Sixty eyes of 60 patients with a mean age of 25± 6.8 years (12-49 years) were enrolled in study. Corneal epithelial defect healed within 75.8± 29.8 days (46-170 days) in the amniotic membrane group versus 72.6 ± 30.4 (21- 180 days) in control group (p=0.610). There was no difference in corneal conjunctivalization/vascularization between two groups (73.3% vs 53.3%, p=0.108). Perilimbal ischemia improved in 76.41±42.8 days in the amniotic membrane group versus 89.16±44.6 days in the control group (p=0.482). Mean final visual acuity was 0.024± 0.655 logMAR versus -0.072± 0.5 logMAR in the amniotic membrane and control groups, respectively (p=0.655).


In comparison to conventional medical therapy, combined amniotic membrane transplantation and medical therapy does not accelerate corneal epithelization or decrease corneal vascularization. AMT does not improve perilimbal ischemia or final visual acuity.

Financial Disclosure:


Back to previous